Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR).
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Bayer/Onyx; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer
Bernard J. Escudier
Consultant or Advisory Role - Bayer/Onyx; Novartis; Pfizer
Honoraria - AVEO; Bayer/Onyx; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche (I)
Thomas Powles
Consultant or Advisory Role - Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline
David Cella
Consultant or Advisory Role - AVEO; Bayer; Exelixis; Novartis; Pfizer
Research Funding - AVEO; Bayer; Novartis; Pfizer
Qinhua C. Ru
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis (B)
Christian Scheffold
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Robert J. Motzer
Consultant or Advisory Role - Pfizer
Research Funding - Exelixis; GlaxoSmithKline; Novartis; Pfizer
Expert Testimony - Pfizer